DEPENDENCE LIABILITY OF " NON-NARCOTIC " DRUGS 47 QUINAZOLINONES Of the two compounds listed (Table VIII), methaqualone (S 120) has been marketed for the longest time. In Japan, many young persons abused methaqualone as long as that drug was available without prescription. The Japanese have also de- scribed convulsions and delirium following with- drawal of methaqualone, indicating that it produces dependence of the barbiturate-alcohol type. Only one report of dependence on methaqualone was found in the western literature.Y0 Some evidence of abuse of a preparation (Mandrax) containing methaqualone and an antihistamine has been reported in British 197-199 and German203 journals. Accordingly, methaqualone, pending the availability of more definitive information, must be regarded as having low to moderate potential for abuse. By chemical and pharmacological analogy, the abuse iability of mecloqualone (S 119) must be rated as equal to that of methaqualone. REFERENCES 197. De Alarcon, R. (1969) Brit. med. J., 1, 122-123 (Methaqualone) 198. De Alarcon, R. (1969) Brit. med. J., 1, 319 (Mandrax and methaqualone) 199. Banady, D. R. (1969) Brit. med. J., 1, 577-578 (Mandrax) 200. Boissier, J. R. & Dumont, C. (1967) Chem. Abstr., 67, 8006, 84843W (Hypnotic) 201. Gitelson, S. (1967) J. Amer. med. Ass., 201, 977-979 (Methaqualone-meprobamate poisoning) 202. Grishina, V. M. (1967) Chem. Abstr., 67, 955, 10188q (Neurotropic properties of certain derivatives of 4-quinazolinone) 203. Ibe, K. (1965) Arch. Toxikol., 21, 179-198 (Acute methaqualone intoxication) 204. Madden, J. S. (1966) Brit. med. J., 1, 676 (Dependen- cy on methaqualone hydrochloride-Melsedin) 205. Pfeiffer, C. C., Goldstein, L. & Murphree, H. B. (1968) J. clin. Pharmacol., 8, 235-244 (Quantita- tive analysis of the effect of methaqualone on the human EEG) 0 0 C 0 0 Q) CN OJN 0 C4 0 )0O; _m a r4 co _m CO V0JC- ~ 00 0 0C 0* E Eo a~~~~~~~~~~~~~~~i 0)n oO .2z . (* ;;l0 to Co ~~~~~~~~ ~~~~~~~(0.'- 00- 0~~~~~~~~~~~0 E 0 0 co O 0 * C CD .C-CO 0. 0 LnU O I~~~~~a.C 0 0 0 .CL a. 0 0 I- 0 a) C U C >to 0 a0 0 E >, '. 05 E 0 .20E aC0 to E-CO 011.0 0 0 0 Z o 0 V 00 C0a 3._ 20 C) 0 C 0 0 0M 0 I 0 0k9 a U) co 0T C BC 0 = -0 S. N C; . C,,U 0 co 0 Z . a0) * 0 o c:a cXca)cL 0 Cr 0(U 0. - 48- U) z 0 z zi0N 4z D On U,) z J U,) W w M 0. w a w Cl) Ul) 0 I- w U w -J M E o oE Io.I E 0Z0Z- C 0- 0. C OZECL o000 10 a C. ZE .COE 0 0c 0 0Z co 01 L0 o-0 C.2 E Coi0C C 0 0 CL> N O 2 L 0 C30L cmE 0 " V) .0C m: 0 0*.. c-O ax, 0- 000 sH ) s-I aE 0 >,0 0 0.Z Ob. 0 .-°O 0. (n o amoo .00 C) > E UOfzMX co 1cm iL- 08 4)QX: co a Icr s M I Z 0 en C tn
World Health Organization (WHO) · Journal articles
Quinazolinones
View original document
The full text is hosted by the publishing organisation. lawenc.com indexes the metadata and links to the official source.
Full text
Key facts
Organisation
World Health Organization (WHO)
Document type
Journal articles
Source
World Health Organization